Association Between Toll-Like Receptors/CD14 Gene Polymorphisms and Inflammatory Bowel Disease in Korean Population by Kim, Eun Jung et al.
© 2012 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Association Between Toll-Like Receptors/CD14 Gene 
Polymorphisms and Inflammatory Bowel Disease in Korean 
Population
The innate immune response in patients who develop inflammatory bowel disease (IBD) 
may be abnormal. However, the exact role of Toll-like receptors (TLRs) / CD14 gene in the 
pathogenesis of IBD has not been fully elucidated. We aimed to investigate the association 
between polymorphisms of TLR1, 2, 4, 6, and CD14 gene and susceptibility to IBD in 
Korean population. A total 144 patients of IBD (99 patients with ulcerative colitis, 45 
patients with Crohn’s disease) and 178 healthy controls were enrolled. Using a PCR-RFLP, 
we evaluated mutations of TLR1 (Arg80Thr), TLR2 (Arg753Gln and Arg677Trp), TLR4 
(Asp299Gly and Thr399Ile), TLR6 (Ser249Pro) genes and the -159 C/T promoter 
polymorphism of CD14 gene. No TLR polymorphisms were detected in Korean subjects. T 
allele and TT genotype frequencies of CD14 gene were significantly higher in IBD patients 
than in healthy controls. In subgroup analysis, T allelic frequency was higher in pancolitis 
phenotype of ulcerative colitis. In Korean population, the promoter polymorphism at -159 
C/T of the CD14 gene is positively associated with IBD, both ulcerative colitis and Crohn’s 
disease. 
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INTRODUCTION
Inflammatory bowel disease (IBD) is a complex disease with 
both genetic and environmental factors necessary for disease 
pathogenesis. Particular genetic changes may influence the sus-
ceptibility to disease and individual variation of disease pattern. 
It has been associated with specific variant alleles (polymor-
phism) of gene that are present in a significant proportion of the 
normal population. Polymorphisms in a wide variety of genes 
may modify the effect of environmental exposures (1). Recent 
genome-wide linkage studies and case-control association stud-
ies have shown several susceptibility regions for IBD (2-4). 
  The innate immune system represents the first defense line 
in preventing infection of bacteria and provides a critical inter-
face between microorganisms and their hosts. It can promptly 
recognize and respond to pathogenic microorganisms. Toll-like 
receptor (TLR) is one of pathogen pattern recognition receptors 
for micro-organism-derived pathogenic molecules (5, 6). Clus-
ters of differentiation 14 (CD14) is a glycoprotein expressed on 
the surfaces of monocytes and macrophages, and acts as a pat-
tern recognition receptor and contributes to TLR-induced cell 
activation (5, 7). Both of TLRs and CD14 are considered as the 
primary sensors of the innate immune system. 
  It has been reported that the -159 C/T polymorphism in the 
CD14 gene plays a significant role in regulating the CD14 expres-
sion by increasing production of TNF-α (8). Previously, several 
studies have reported on the association between IBD and TLRs/ 
CD14 gene polymorphism (9-15), but there are no consistent 
results. Different results may be interpreted by genetic hetero-
geneity of races. Until now, in Korean population, whether TLRs/ 
CD14 gene polymorphism is associated with IBD remains un-
known.
  In this study, we aimed to investigate the frequencies of TLR1, 
2, 4, 6, and CD14 gene polymorphism in patients with IBD, and 
evaluate the association between those polymorphisms and the 
susceptibility to IBD in Korean population.
 
MATERIALS AND METHODS
Subjects
Healthy control subjects and IBD (ulcerative colitis [UC] and 
Crohn’s disease [CD]) patients were enrolled from a teaching 
hospital of the Catholic University of Medicine, St. Vincent’s hos-
pital, from September 2007 to February 2008. A diagnosis of UC Kim EJ, et al.  •  TLRs/CD14 Gene Polymorphisms in IBD
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was made if all the following three criteria were present: a typi-
cal history of diarrhea or blood and pus in stool for longer than 
4 weeks; a typical sigmoidoscopic or colonoscopic picture with 
diffusely granular, friable, or ulcerated mucosa without rectal 
sparing; and characteristic histopathological signs of infiamma-
tion on biopsy (16). Diagnosis of CD was based on the official 
criteria established by the research committee of the Japan Min-
istry of Health and in Western countries (17, 18). Healthy con-
trol subjects were asymptomatic and randomly selected from 
subjects attending regular health screening at the Health Pro-
motion Center of the same hospital. They were not affected with 
colon by endoscopic examination or double contrast barium 
enema. Blood samples of 10 mL were obtained from all subjects 
and collected in a test tube containing EDTA or heparin. 
Classification
Chronic UC patients were classified according to the location 
and extension of inflammatory lesions judged by endoscopic 
findings, the disease activity index following Mayo score, and 
the need for or the response of steroid and immunomodulator 
therapy. Chronic CD patients were classified according to the 
location of lesions and the disease behavior following Montreal 
classification (19), and the need for or the response of steroid and 
immunomodulator therapy. Patients who failed to respond to 
steroid over a period of 4 weeks were defined as ‘steroid refrac-
tory’ . Patients who initially responded to steroid but then relapsed 
during tapering, and required re-introduction of steroid therapy 
to maintain symptoms control, were defined as ‘steroid depen-
dent’ (20).
Polymorphism analysis
Genomic DNA was obtained from buffy-coat leukocytes using 
the AccuPrep Genomic DNA Extraction Kit (Bioneer Corpora-
tion, Daejeon, Korea). The CD14 promoter C(-159)T, TLR1 Ar-
g80Thr, TLR2 Arg677Trp, TLR2 Arg753Gln, TLR4 Asp299Gly, 
TLR4 Thr399Ile, TLR6 Ser249Pro polymorphisms were per-
formed using the polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) method.
  PCR reactions were set up using the i-Star Taq DNA poly-
merase (iNtRON Biotechnology, Seoul, Korea). In a total reac-
tion volume of 20 μL, 2 μL 10 ×  buffer, 10 pM each primer, 2 μL 
genomic DNA, 2 μL dNTP mixture were combined. Reactions 
were run on a Bio-Rad MyCycler thermal cyclers (BIO-RAD, Phil-
adelphia, PA, USA). The primer sequences for amplifying each 
SNP were shown in Table 1. The PCR conditions were as follows: 
an initial denaturation at 95°C for 5 min, followed by 35 cycles 
of denaturing at 94°C for 30 sec, annealing for 30 sec, extension 
at 72°C for 30 sec and final incubation at 72°C for 10 min and 
cooling to 4°C. For 16 hr, the PCR products (3 μL) were used for 
an overnight digest with the appropriate restriction enzyme 
(Table 1), and digests were analyzed by electrophoresis in a 3% 
agarose gel. 
Statistical analysis 
The data were analyzed using SPSS software (version 15.0, SPSS, 
Chicago, IL, USA). Genotype and allele frequencies were calcu-
lated by direct counting. Significance of association was deter-
mined by chi-square tests or Fisher’s exact test. Departures from 
Hardy-Weinberg equilibrium in patients and healthy controls 
were tested by the chi-square method. Continuous data were 
expressed as mean ± standard deviation and were analyzed us-
ing independent samples t-tests. A P value < 0.05 was consid-
ered significant for all the tests. For subgroup analysis, Bonfer-
roni correction was made for the multiple comparisons. 
Ethics statement
This study was approved by the institutional review board of the 
Catholic University of Korea (VCMC07BR047). Written informed 
consent was obtained from all subjects after a full explanation 
of the project.
Table 1. The primer sequences, annealing time, restriction enzymes, and digest time used for PCR-RFLP methods detecting the each single nucleotide polymorphism (SNP)
SNP                Forward primer Reverse primer
Annealing Tm 
(°C)
Allele
Restriction  
enzyme
Digest Tm (°C)
CD14 5´-ATCATCCTTTTCCCACACC-3´
5´-AACTCTTCGGCTGCCTCT-3´
64 C/T HaeIII 37
TLR1 R80T 5´-TCTGAGCTTTGGACTTCTGACA-3´
5´-AGGGTGGCAAGAAATCTTCA-3´
53 C/G HinfI 37
TLR2 A677T 5´-CCCCTTCAAGTTGTGGCTTCATAA-3´
5´-AGTCCAGTTCATACTTGCACCAC-3´
58 A/G MwoI 60
TLR2 A753G 5´-CATTCCCCAGCGCTTCTGCAAGCTCC-3´
5´-GGAACCTAGGACTTTATCGCAGCTC-3´
65 A/G MspI 37
TLR4 A299G 5´-GATTAGCATACTTAGACTACTACCTCCATG-3´
5´-GATCAACTTCTGAAAAAGCATTCCCAC-3´
61 A/G NcoI 37
TLR4 T399I 5´-GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-3´
5´-CCTGAAGACTGGAGAGTGAGTTAAATGCT-3´
61 C/T HinfI 37
TLR6 S249P 5´-GAATGCAAAAACCCTTCACC-3´
5´-TGGGCCAAAGAAATTGAAAG-3´
53 C/T AvaII 37
Tm, temperature.Kim EJ, et al.  •  TLRs/CD14 Gene Polymorphisms in IBD
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RESULTS
Demographic characteristics of patients
A total of 144 IBD patients and 178 healthy control subjects were 
enrolled in the study. There were no significant differences in 
age and sex between the two groups. The demographic charac-
teristics of the patients with UC and CD were shown in Table 2. 
TLR polymorphisms
Arg80Thr of TLR 1, Arg677Trp of TLR2, Arg753Gln of TLR2, Asp-
299Gly of TLR4, Thr399Ile of TLR4 and Ser249Pro TLR6 gene 
polymorphisms were not detected in healthy control subjects 
and IBD patients.
CD14 polymorphisms
Digestion of the PCR products for the promoter polymorphism 
at -159 C/T of the CD14 gene yielded bands of 295 bp in TT ho-
mozygotes, 140 and 155 bp in CC homozygotes, and all 3 bands 
(140, 155, and 295 bp) in heterozygotes (Fig. 1). The frequencies 
of TT genotype and T allele of the CD14 gene were significantly 
higher in IBD patients than in healthy control group (TT, 32.6% 
in IBD vs 14.6% in control, P < 0.01; T allele, 0.57 in IBD vs 0.34 
in healthy control, P < 0.01). The frequencies of TT and T allele 
in each of UC and CD patients were also significantly higher 
than in controls (Table 3). 
  A total 45 patients with CD assigned to divide into the sub-
groups according to the Montreal classification. There were no 
Table 2. Demographic characteristics of patients with ulcerative colitis and Crohn’s 
disease
Parameters
Ulcerative colitis 
(n = 99)
Crohn’s disease 
(n = 45)
Healthy control 
(n = 178)
Age (yr) (mean ± SD) 49.8 ± 14.7 32.1 ± 11.4 47.2 ± 13.0
Male:female 46:53 25:20 88:90
Age at diagnosis (yr)  
   (mean ± SD)
41.9 ± 14.4 27.4 ± 10.8
Disease duration (yr)  
   (mean ± SD)
7.9 ± 4.6 5.3 ± 5.4
Table 3. Allele and genotype frequencies of the promoter polymorphism at -159 C/T 
of the CD 14 gene
No.
Genotypes Allele frequencies
CC (%) CT (%) TT (%) C T
IBD
   CD
   UC
144
  45
  99
28 (19)
9 (20)
19 (19)
69 (48)
17 (38)
52 (53)
47 (33)*
19 (42)*
28 (28)*
0.43
0.39
0.45
0.57
†
0.61
‡
0.55
§
Control 178 74 (41) 78 (44) 26 (15) 0.63 0.37
*P < 0.001 vs control; 
†P < 0.005; 
‡P < 0.001; 
§P < 0.01. CD, Crohn’s disease; UC, 
ulcerative colitis.
Table 4. Allele and genotype frequencies of the promoter polymorphism at -159 C/T of the CD14 gene in patients with Crohn’s disease
Parameters No.
Genotypes Allele frequencies
CC (%) CT (%) TT (%) C T
Location
   L1
   L2
   L3
   L4
 
11
10
21
  3
 
2
2
6
1
 
  6
  4
  6
  0
 
  3
  4
  9
  2
 
0.45
0.40
0.43
0.33
 
0.55
0.60
0.57
0.67
Behavior
   B1
   B2
   B3
 
23
10
12
 
5
2
1
 
  7
  5
  6
 
11
  3
  5
 
0.37
0.45
0.33
 
0.63
0.55
0.67
Steroid response
   No use
   Initial induction only
   Intermittent 
   Refractory or dependent
 
17
19
  6
  3
 
4
2
1
2
 
  6
  8
  2
  1
 
  7
  9
  3
  0
 
0.41
0.32
0.33
0.83
 
0.59
0.68
0.67
0.17
Immunomodulator
   No use
   Temporary
   Maintenance
 
14
  2
29
 
3
1
5
 
  5
  0
12
 
  6
  1
12
 
0.39
0.50
0.38
 
0.61
0.50
0.62
L1, terminal ileum; L2, colon; L3, ileocolon; L4, upper GI proximal to the terminal ileum; B1, nonstricturing nonpenetrating; B2, structuring; B3, penetrating.
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Fig. 1. Detection for the -159C/T polymorphism of CD14 gene by using PCR-RFLP. 
Digestion of the PCR products yielded bands of 295 bp in TT homozygotes, 140 and 
155 bp in CC homozygotes, and all 3 bands (140, 155, and 295 bp) in heterozygotes. Kim EJ, et al.  •  TLRs/CD14 Gene Polymorphisms in IBD
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significant differences in TT genotype and T allele frequencies 
of CD14 gene according to the disease location and behavior, 
the administration of steroid or immunomodulator, and the re-
sponse to treatment (Table 4). Among 99 patients with UC, 24 
patients (22.2%) had pancolitis, while 23 patients had the dis-
ease limited to the left side and 52 patients had proctitis. In pa-
tients with UC, TT and T allele were not associated with the dis-
ease activity, the use of steroid or immunomodulator, and the 
response to each drug, but associated with the disease extent (T 
allele: 0.65 in pancolitis vs 0.51 in left-sided colitis and proctitis, 
P = 0.01) (Table 5) (Fig. 2). 
DISCUSSION 
Although the exact etiology of IBD is unknown, it is considered 
that inappropriate and exaggerated immune response to lumi-
nal bacteria would be an important role in the pathogenesis of 
IBD. In the past, numerous endogenous, pathogenic bacteria 
or mycobacteria have long been suspected as being major con-
tributors to the etiology of IBD, but none of them have achieved 
etiologic status (21). Inappropriate activation of innate immuni-
ty is the other arm involved in the pathogenesis of IBD. Recent-
ly, genetic studies in humans and mice have made a convincing 
link between the innate immune system and chronic inflamma-
tion (22, 23). 
  Epidemiological studies show an association between TLR4 
polymorphism and susceptibility to IBD. In a Belgian study, the 
allele frequency of the TLR4 A299G polymorphism was signifi-
cantly higher in CD and in UC patients compared with controls, 
whereas no association with IBD of the TLR4 polymorphim was 
found in Hungarian and German cohort (24, 25). The study about 
polymorphisms of TLR1, 2 or 6 in the pathogenesis of IBD are 
scarce. None of the single nucleotide polymorphisms of TLR1, 
2 or 6 were involved with IBD susceptibility. However, a num-
ber of variants were found to be associated with disease pheno-
types. The TLR2 R753G and TLR1 R80T single nucleotide poly-
morphisms (SNPs) were found to be associated with pancolitis 
in UC (26). In our results, gene polymorphisms of the TLRs were 
not detected in any Korean subject. It suggested that the contri-
bution of genetic determinants might differ significantly between 
ethnicities.
  CD14 gene consists of a single base substitution (C → T) at 
position -159 in the promoter of the gene (27). This polymor-
phism has been reported to influence degree of the density of 
CD14 expression to secrete inflammatory cytokines by lipopoly-
saccharide (LPS) (28). Previously, in several reports from West-
ern countries, gene polymorphisms of the CD14 was found to 
be associated with the development of IBD, more so in the de-
velopment of CD than in UC (9, 10). However, in Japanese pop-
%
	 Proctitis	+	Left	side	 Pancolitis	
	 colitis
T	allele
C	allele
100
50
0
51
65
49
35
P	<	0.01
Fig. 2. Allele frequency of the promoter polymorphism at -159 C/T of the CD14 gene 
according to disease extent in patients with ulcerative colitis. 
Table 5. Allele and genotype frequencies of the promoter polymorphism at -159 C/T of the CD14 gene in patients with ulcerative colitis 
Disease status No
Genotypes Allele frequencies
CC (%) CT (%) TT (%) C T
Extent
   Proctitis
   Left-sided colitis
   Pancolitis
 
52
23
24
 
12
6
2
 
25
12
13
 
15
5
9
 
0.47
0.52
0.35
 
0.53
0.48
0.65
Disease activity
   Mild
   Moderate
   Severe
 
35
46
18
 
8
9
4
 
17
23
9
 
10
14
5
 
0.47
0.45
0.47
 
0.53
0.55
0.53
Steroid response
   No use
   Initial induction only
   Intermittent 
   Dependent
 
49
14
19
17
 
8
6
2
4
  
26
3
13
9
 
15
5
4
4
 
0.43
0.54
0.45
0.50
 
0.57
0.46
0.55
0.50
Immunomodulator
   No use
   Temporary
   Maintenance
 
72
  9
18
 
16
2
4
 
32
3
11
 
24
4
3
 
0.44
0.39
0.53
 
0.56
0.61
0.47Kim EJ, et al.  •  TLRs/CD14 Gene Polymorphisms in IBD
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ulation, the same genotype is associated with UC but not with 
CD (12, 15), and another study investigating Chinese patients 
failed to demonstrate any association (13). In our results, T allele 
and TT genotype frequencies of CD14 gene were significantly 
higher in IBD patients than in healthy controls. In subgroup anal-
ysis, both CD and UC patients had significantly higher T allele 
frequency compared to healthy controls. In patients with UC 
and CD, T allele and TT genotype frequencies of CD14 gene were 
not associated with the disease activity, the use of steroid or im-
munomodulator and the response to each drug. It is notewor-
thy that the specific allelic frequency of CD14 polymorphism is 
closely associated with pancolitis phenotype in UC. Since this 
study includes small numbers of the patients with IBD, especial-
ly with CD, it might be difficult to figure out the association be-
tween genetic polymorphism and disease phenotype. Moreover, 
it cannot exclude a type 2 statistical error. To overcome it, the re-
searcher can sample as many subjects as cost and time allow. 
  The distributions of CD14 -159C/T genotypes were signifi-
cantly different between Korean and Chinese, and between Ko-
rean and Japanese population, which demonstrated ethnic ge-
netic differences. Compared with the previous studies, the fre-
quency of the CC genotype of healthy controls in Korean popu-
lation (41.6%) was higher than in Chinese (15.6%) or Japanese 
(21.8%), whereas the TT genotype of healthy controls in Korean 
(14.6%) was lower than in Chinese (36.3%) or Japanese (25.4%) 
(12, 13). Further study in larger and diverse populations would 
be needed for elucidation of the association between disease 
susceptibility of IBD and polymorphism of CD14 gene.
  In conclusion, the promoter polymorphism at -159 C/T of the 
CD14 gene is positively associated with IBD, both UC and CD. In 
patients with UC, T allele and TT genotype frequencies of CD14 
gene are associated with the disease extent, and increased T al-
lelic frequency is preferable to pancolitis phenotype of UC in 
Korean population. 
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